T cell immunoglobulin domain and mucin domain-containing molecule 3 (TIM-3) is found expression in the surface of terminally differentiated T cells and belongs to the TIM family of type Ⅰ transmembrane proteins. It binds to the ligand Galectin-9 and mediates T cell apoptosis. As the research progresses, TIM-3 is also expressed in Th17, NK, monocyte, which binds to ligand and induce immune peripheral tolerance in both mice and man. Numerous researches have demonstrated that TIM-3 influences liver diseases, including liver-associated chronic viral infection, liver fibrosis, liver cancer et al and suggest new approaches to intervention. Currently, targeted therapy of TIM-3 is a new treatment in the field of immunization. Although many studies have proven that TIM-3 has an inhibitory effect in vivo, the specific mechanism is not clear. Herein, we summarize the important role of TIM-3 in the regulation of liver disease and prospects for future clinical research. TIM-3 will provide new targets for improving clinical liver disease.

中文翻译：

---

TIM-3：肝脏疾病中的新兴靶标。

发现T细胞免疫球蛋白结构域和含粘蛋白结构域的分子3（TIM-3）在终末分化T细胞表面表达，属于Ⅰ型跨膜蛋白TIM家族。它与配体Galectin-9结合并介导T细胞凋亡。随着研究的进展，TIM-3也表达于Th17，NK，单核细胞中，它与配体结合并在小鼠和人体内诱导免疫性外周耐受。大量研究表明，TIM-3影响肝脏疾病，包括肝脏相关的慢性病毒感染，肝纤维化，肝癌等，并提出了新的干预方法。当前，TIM-3的靶向疗法是免疫领域中的新疗法。尽管许多研究已经证明TIM-3在体内具有抑制作用，但具体机制尚不清楚。在这里 我们总结了TIM-3在调节肝脏疾病中的重要作用以及未来临床研究的前景。TIM-3将为改善临床肝病提供新的靶标。